Dynasty Wealth Management LLC Invests $3.27 Million in AstraZeneca PLC $AZN

Dynasty Wealth Management LLC purchased a new position in AstraZeneca PLC (NASDAQ:AZN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 42,573 shares of the company’s stock, valued at approximately $3,266,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Primecap Management Co. CA raised its stake in shares of AstraZeneca by 1.3% during the 2nd quarter. Primecap Management Co. CA now owns 41,200,091 shares of the company’s stock worth $2,879,062,000 after purchasing an additional 538,606 shares during the period. Franklin Resources Inc. increased its position in shares of AstraZeneca by 0.9% in the second quarter. Franklin Resources Inc. now owns 21,298,394 shares of the company’s stock worth $1,488,332,000 after purchasing an additional 196,401 shares during the last quarter. Fisher Asset Management LLC raised its position in AstraZeneca by 2.6% during the second quarter. Fisher Asset Management LLC now owns 20,695,979 shares of the company’s stock valued at $1,446,235,000 after purchasing an additional 530,520 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of AstraZeneca by 15.2% in the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock worth $850,255,000 after acquiring an additional 1,605,133 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of AstraZeneca by 2.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,046,992 shares of the company’s stock valued at $351,734,000 after acquiring an additional 104,625 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Trading Up 0.4%

Shares of AstraZeneca stock opened at $94.39 on Tuesday. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $96.51. The stock has a market cap of $292.78 billion, a PE ratio of 31.36, a price-to-earnings-growth ratio of 1.57 and a beta of 0.34. The firm has a fifty day moving average price of $91.66 and a 200 day moving average price of $83.08. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.05. The business had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The business’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.08 EPS. Equities research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on AZN shares. Guggenheim reissued a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Wall Street Zen cut shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday. Jefferies Financial Group initiated coverage on AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a research report on Friday. Finally, HSBC reiterated a “buy” rating and issued a $108.00 target price on shares of AstraZeneca in a research report on Wednesday, December 10th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, AstraZeneca has an average rating of “Moderate Buy” and an average price target of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.